Development of a novel microbiota-based therapy for the prevention of type 2 diabetes mellitus.
PROMISE will deliver an innovative microbiota-based therapy based upon the anaerobic human derived butyrate-producing bacterium Eubacterium hallii, for the reduction of insulin resistance and prevention of type 2 diabetes mellitus (T2DM) in individuals suffering from metabolic syndrome (MetS). Additionally, this project adopts a novel approach aiming to set new standards in performing (pre)clinical studies using a microbial therapy in stratified target groups.
1 872 200.00€
Nutrition and Health